TY - JOUR
T1 - Treatment decision-making among patients with metastatic prostate cancer
T2 - Impact of decision locus of control on functional outcomes and decision satisfaction
AU - Schumacher, Frank A.
AU - Helenowski, Irene B.
AU - Sun, Zequn
AU - Oswald, Laura B.
AU - Gonzalez, Brian D.
AU - Moses, Kelvin A.
AU - Benning, James T.
AU - Morgans, Alicia Katherine
N1 - Funding Information:
We assessed DLOC following a clinic visit in which a treatment decision occurred (baseline), and assessed patient-reported functional outcomes at baseline, 2-months post-treatment decision, and 4-months post-treatment decision. We evaluated patient-reported preferences for DLOC among mPC patients following a clinic visit in which a treatment decision had occurred. Treatment decisions included any decision to change the treatment approach to the prostate cancer, associated pain or comorbidities, or to maintain the current treatment approach. This study was approved by the Institutional Review Board at Vanderbilt University Medical Center (VUMC; approval #161441) and Northwestern Memorial Hospital (NMH, approval #STU00206080). Between 2018 and 2020, patients with mPC were recruited from Genitourinary Oncology clinics at VUMC and NMH, with an accrual goal of 94 patients. Eligible patients spoke English, were able to recall a decision at a clinic visit within the preceding 48 h and signed informed consent to participate. There were no restrictions or requirements regarding prior local or systemic treatment exposure. Patients completed electronic surveys describing the decision-making process, decision satisfaction, and quality of life (QOL) outcomes via REDCap on tablets in clinic. Patient sociodemographic and clinical characteristics, including age, race/ethnicity, marital/partner status, self-reported health status (i.e., excellent, good, fair, or poor), and insurance status were collected by patient self-report and electronic medical record when possible to reduce missing data. The study was supported by a grant from the Department of Defense Prostate Cancer Research Program (PC150398).
Funding Information:
This work was supported by the Department of Defense Physician Research Training Award PC150398.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2023/3
Y1 - 2023/3
N2 - Background: Shared decision-making (SDM) for metastatic prostate cancer (mPC) engages patients in the decision-making process and may be associated with better outcomes relative to physician- or patient-directed decision-making. We assessed the association between decision locus of control (DLOC) and patient-reported quality of life (QOL), functional outcomes, and decision satisfaction among mPC patients. Methods: After a clinic visit in which a treatment decision was made (baseline), mPC patients completed DLOC and QOL surveys. QOL was re-assessed at 2- and 4-months post-baseline. Mean scores for each QOL dimension (physical, emotional, cognitive, social, and role functioning) were compared by DLOC group using mixed effects models. Patient preferences for DLOC and provider communication techniques were similarly collected via survey. Results: Median age of participants (N = 101) was 69 years (range: 49-92); most were White (80%) and married (82%). 62% reported using SDM. At baseline, there were no differences in QOL dimensions between DLOC groups. At 4 months, patient-directed (p = 0.01) and SDM (p = 0.03) were associated with better physical functioning than physician-directed decision-making, and there was an indication of potentially greater decision satisfaction among patients who reported patient-directed (p = 0.06) or SDM (p = 0.10). SDM was the most reported preferred DLOC. Conclusion: mPC patients reporting SDM had better physical functioning at 4 months than physician- or patient-directed decision-making, suggesting measurable benefit from patient involvement in decision-making. Future investigations of these associations in larger, more diverse populations can further clarify these previously unmeasured benefits of patient engagement in treatment decisions.
AB - Background: Shared decision-making (SDM) for metastatic prostate cancer (mPC) engages patients in the decision-making process and may be associated with better outcomes relative to physician- or patient-directed decision-making. We assessed the association between decision locus of control (DLOC) and patient-reported quality of life (QOL), functional outcomes, and decision satisfaction among mPC patients. Methods: After a clinic visit in which a treatment decision was made (baseline), mPC patients completed DLOC and QOL surveys. QOL was re-assessed at 2- and 4-months post-baseline. Mean scores for each QOL dimension (physical, emotional, cognitive, social, and role functioning) were compared by DLOC group using mixed effects models. Patient preferences for DLOC and provider communication techniques were similarly collected via survey. Results: Median age of participants (N = 101) was 69 years (range: 49-92); most were White (80%) and married (82%). 62% reported using SDM. At baseline, there were no differences in QOL dimensions between DLOC groups. At 4 months, patient-directed (p = 0.01) and SDM (p = 0.03) were associated with better physical functioning than physician-directed decision-making, and there was an indication of potentially greater decision satisfaction among patients who reported patient-directed (p = 0.06) or SDM (p = 0.10). SDM was the most reported preferred DLOC. Conclusion: mPC patients reporting SDM had better physical functioning at 4 months than physician- or patient-directed decision-making, suggesting measurable benefit from patient involvement in decision-making. Future investigations of these associations in larger, more diverse populations can further clarify these previously unmeasured benefits of patient engagement in treatment decisions.
UR - http://www.scopus.com/inward/record.url?scp=85146952046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146952046&partnerID=8YFLogxK
U2 - 10.1038/s41391-023-00647-5
DO - 10.1038/s41391-023-00647-5
M3 - Article
C2 - 36709235
AN - SCOPUS:85146952046
SN - 1365-7852
VL - 26
SP - 201
EP - 206
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 1
ER -